VJHemOnc is committed to improving our service to you

ISA 2020 | The evolution of AL amyloidosis therapy

VJHemOnc is committed to improving our service to you

Joel Buxbaum

Many therapies for AL amyloidosis are derived from treatments commonly used for multiple myeloma, with initial trials investigating melphalan and prednisone. In this video Joel Buxbaum, MD, Scripps Research, La Jolla, CA, tells us about the evolution of AL amyloidosis therapy, delineating the trend of regimens that parallel that of multiple myeloma and commenting on alternative therapies such as TUDCA, doxycycline and epigallocatechin-3-gallate. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter